According to the latest filing with the U.S. Securities and Exchange Commission (SEC), Apimeds Pharmaceuticals US Inc (APUS) has officially announced two key executive appointments: Mr. Cho as Chief Executive Officer (CEO) and Mr. Yu as Secretary.

Both appointments take immediate effect from the date of this announcement. This senior management change marks an important step forward for APUS in strategic execution and corporate governance. The new CEO, Mr. Zhao, will be fully responsible for the company’s overall operations and business direction, while Mr. Yu, as secretary, will assist in strengthening corporate compliance management and information disclosure matters. The company did not further disclose detailed backgrounds or specific role divisions of the two executives in the document. The market is watching closely to see whether this personnel adjustment will bring new development strategies or business restructuring to Apimeds Pharmaceuticals US Inc.